Actinium Pharmaceuticals Inc (ATNM)

$1.63 -0.05 (-2.98%)
Market Cap 52.41M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 102,700
Avg Vol 183,528
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 42%
Beta -0.30
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
1Hamfredbuttlington
1Hamfredbuttlington Sep. 12 at 11:19 PM
$ATNM i just need 3 billion Seth, thats all. Whatever it takes....😄
0 · Reply
Pinto72
Pinto72 Sep. 12 at 10:09 PM
$ATNM Will never generate revenue, and will never be bought out🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣 HELLOOOOOOO, GEORGE!!!!!!! BANKRUPTCY = AS SOON!!!!🤣🤣🤣🤣🤣
0 · Reply
LosStockosDiablo
LosStockosDiablo Sep. 12 at 4:00 PM
$ATNM Bought a small position this morning for a long term hold.
0 · Reply
gooddoggie
gooddoggie Sep. 12 at 7:08 AM
$ATNM And for today’s edition of New Products You Didn’t Know You Need: Dude Wipes!
1 · Reply
excobito
excobito Sep. 12 at 12:32 AM
$ATNM will it be another random spike Friday? I've got my sell order already in!
1 · Reply
tjm1
tjm1 Sep. 11 at 8:45 PM
$ATNM Memories.....SP down $70 or 97% since Seth took over AND during that same time frame, Seth has comped himself how much?
0 · Reply
ckruel
ckruel Sep. 11 at 4:24 PM
$ATNM Read this, a complete update on atnm https://beyondspx.com/quote/ATNM/analysis/actinium-pharmaceuticals-alpha-emitter-innovation-driving-a-strategic-pivot-nyseamerican-atnm
1 · Reply
ckruel
ckruel Sep. 11 at 4:24 PM
$ATNM
0 · Reply
fede5910
fede5910 Sep. 11 at 2:48 PM
$ATNM ATNM today 1.65 if ATNM is sold for 1 billion, a giveaway, the value of the share is 25. The truth is it's worth taking any risk, the emergency exit is already open to dodge any possible threats.
2 · Reply
RadioIsotope25
RadioIsotope25 Sep. 11 at 1:30 AM
$RADX “We are pleased to make a strategic investment in RAD and partner with them to further expand our innovative pipeline,” said Brian Markison, Chief Executive Officer of Lantheus. “Radiopharmaceutical theranostics are changing the way cancer is diagnosed and treated, yet we still have more work to do and are inspired to further advance this field with these two preclinical oncology assets. $LNTH $ATNM $CSBR
3 · Reply
Latest News on ATNM
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 6 weeks ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 2 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 4 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 4 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 4 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 5 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 5 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 6 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 6 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 25, 2025, 6:00 AM EDT - 6 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 24, 2025, 4:15 PM EDT - 6 months ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Mar 20, 2025, 8:00 AM EDT - 6 months ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Mar 19, 2025, 8:30 AM EDT - 6 months ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

1Hamfredbuttlington
1Hamfredbuttlington Sep. 12 at 11:19 PM
$ATNM i just need 3 billion Seth, thats all. Whatever it takes....😄
0 · Reply
Pinto72
Pinto72 Sep. 12 at 10:09 PM
$ATNM Will never generate revenue, and will never be bought out🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣 HELLOOOOOOO, GEORGE!!!!!!! BANKRUPTCY = AS SOON!!!!🤣🤣🤣🤣🤣
0 · Reply
LosStockosDiablo
LosStockosDiablo Sep. 12 at 4:00 PM
$ATNM Bought a small position this morning for a long term hold.
0 · Reply
gooddoggie
gooddoggie Sep. 12 at 7:08 AM
$ATNM And for today’s edition of New Products You Didn’t Know You Need: Dude Wipes!
1 · Reply
excobito
excobito Sep. 12 at 12:32 AM
$ATNM will it be another random spike Friday? I've got my sell order already in!
1 · Reply
tjm1
tjm1 Sep. 11 at 8:45 PM
$ATNM Memories.....SP down $70 or 97% since Seth took over AND during that same time frame, Seth has comped himself how much?
0 · Reply
ckruel
ckruel Sep. 11 at 4:24 PM
$ATNM Read this, a complete update on atnm https://beyondspx.com/quote/ATNM/analysis/actinium-pharmaceuticals-alpha-emitter-innovation-driving-a-strategic-pivot-nyseamerican-atnm
1 · Reply
ckruel
ckruel Sep. 11 at 4:24 PM
$ATNM
0 · Reply
fede5910
fede5910 Sep. 11 at 2:48 PM
$ATNM ATNM today 1.65 if ATNM is sold for 1 billion, a giveaway, the value of the share is 25. The truth is it's worth taking any risk, the emergency exit is already open to dodge any possible threats.
2 · Reply
RadioIsotope25
RadioIsotope25 Sep. 11 at 1:30 AM
$RADX “We are pleased to make a strategic investment in RAD and partner with them to further expand our innovative pipeline,” said Brian Markison, Chief Executive Officer of Lantheus. “Radiopharmaceutical theranostics are changing the way cancer is diagnosed and treated, yet we still have more work to do and are inspired to further advance this field with these two preclinical oncology assets. $LNTH $ATNM $CSBR
3 · Reply
gooddoggie
gooddoggie Sep. 10 at 2:26 PM
$ATNM President Trump speaking about the ATNM lawsuit: “This witch-hunt against Lil’ Seth is a radical left-wing hoax and I’m not happy”.
1 · Reply
Snookville
Snookville Sep. 10 at 1:47 PM
$ATNM red hot start to the day baby
0 · Reply
winners18
winners18 Sep. 10 at 2:53 AM
$ATNM https://endpoints.news/sp/the-new-blueprint-for-biotech-rna-editing-and-radioligand-therapy/#
1 · Reply
dm4
dm4 Sep. 10 at 2:04 AM
$ATNM "Revolutionary Cancer Therapy Clinical Trial Using DOE’s Accelerator-Produced Actinium-225 Launches This Summer" - validates demand for cyclotron produced actinium https://bioengineer.org/revolutionary-cancer-therapy-clinical-trial-using-does-accelerator-produced-actinium-225-launches-this-summer/
0 · Reply
dm4
dm4 Sep. 10 at 1:48 AM
$ATNM More solid tumors....."First Patient With Breast Cancer Dosed With Novel Radioactive Medicine" https://www.curetoday.com/view/first-patient-with-breast-cancer-dosed-with-novel-radioactive-medicine
0 · Reply
timfris
timfris Sep. 9 at 11:41 PM
$ATNM the FDA has been firm since 2020, that the company needs to run another trial for Iomab. The company basically ignored them. The FDA will not reward that. Did you read the lawsuit filings? Sandesh Seth has most likely committed fraud, and probably Steve O, also. They are complete POS’s. There were 3 whistleblowers, high up in the company. They are jeopardizing their careers coming forward. There is not a doubt in my mind they are being truthful and felt it was their duty to tell the truth. Without them gone, the company is not serious about moving forward.
0 · Reply
dm4
dm4 Sep. 9 at 9:56 PM
$ATNM “💡 10 Radiopharma Companies to Watch! From Lu-177 & Cu-67 to Ac-225 & Pb-212, radiopharmaceuticals are reshaping #oncology with novel isotopes, pivotal trials, and fresh financing. At @Biopharmiq_B2B, we’ve mapped 119 radiopharma players worldwide. 👉 Who’s on your radar?” https://x.com/biopharmiq_b2b/status/1965454973262811490?s=12&t=OgLhSpWTIRlbsCZBSb2a-w
3 · Reply
dm4
dm4 Sep. 9 at 6:23 PM
$ATNM Novartis to acquire Tourmaline Bio for $1.4 billion | Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-tourmaline-bio-14-billion-2025-09-09/
1 · Reply
janlukas
janlukas Sep. 9 at 1:05 PM
$ATNM Cwd + 2200% now in pre market without any news, from $2 yesterday it is now $50, it will probably touch $100 during the day. We have the science, it's time for big spikes, come on, let's do it!
1 · Reply
fede5910
fede5910 Sep. 9 at 12:33 PM
$ATNM The only way to overcome the challenges that ATNM is facing today is to move forward, to work for the FDA to reconsider the response regarding Iomab B and to achieve approval, or to accelerate the processes for its conduct and present them to the market to sell the company. Moving forward is how we get out of this situation. If we achieve FDA approval for Iomab B, in my view, the lawsuit is dismissed. Selling the company would provide funds for the ongoing lawsuit. Despite the current situation, I believe we have sufficient reasons for either of the two scenarios.
1 · Reply
johnny4cures
johnny4cures Sep. 8 at 11:28 PM
$ATNM
0 · Reply
tjm1
tjm1 Sep. 8 at 11:11 PM
$ATNM Steve O driving to work in the company car
0 · Reply